All of these adverse conditions coincide in severe sepsis, where AGs are applied under pro-inflammatory conditions, potentially contributing to a strong and health-relevant suppression of SELENOP biosynthesis and interruption of SELENOP-dependent Se-transport to target organs. This evidence concerns the gene SELENOP and Sepsis.